17β-HSD1-IN-1 (Compound 1) is a highly selective 17β-HSD1 inhibitor with IC50s of 5.6 and 3155 nM for 17β-HSD1 and 17β-HSD2, respectively. 17β-HSD1-IN-1 can be used for the research of non-small cell lung cancer (NSCLC)[1].
[1]. Emanuele M Gargano, et al. 17β-droxysteroid Dedrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer. ACS Med Chem Lett. 2021 Nov 18;12(12):1920-1924.
















